Table 2.
Breast cancer cases analyzed and classified according to St. Gallen consensus 2013
| Breast cancer phenotype | Main clinical features | Cases % (n = 47) | Expression of | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ER | PR | HER-2 (score) | Ki67 | LOX-1 | FASN | LOX-1 preeminent isoforms | |||
| Cytoplasm | Nucleus | ||||||||
| Luminal A | > 60% | > 20% | ≤1+ | <14% | 60% | + | ++ | 40% | LOX-1Δ4 |
| HER-2 enriched | − | − | ≥2+ | NA | 20% | +++ | + | 90% | LOX-1 |
| Triple negative | − | − | ≤1+ | NA | 20% | ++ | + | 40% | LOX-1 |
ER estrogens receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2, NA not applicable